Document is current
Any future updates will be listed below
-
Authors
Hoslett, Gwendoline
Tribble, Sara
Lascaux, Pauline
Koukouravas, Stelios
Torrecilla, Ignacio https://orcid.org/0000-0003-4283-0283
Song, Wei https://orcid.org/0000-0002-2834-5671
Hou, Cynthia X.
Li, Junyi
González-Fernández, Martín https://orcid.org/0009-0006-8308-5493
De Gregoriis, Giuliana https://orcid.org/0000-0002-7857-0658
Dagg, Rebecca A. https://orcid.org/0000-0002-3023-9616
O’Brien, Darragh https://orcid.org/0000-0003-4924-7795
Pierangelini, Andrea https://orcid.org/0009-0009-9396-619X
Martial, Thibaud
Ng, Alvin Wei Tian
Raimundo, Nuno https://orcid.org/0000-0002-5988-9129
Milosevic, Ira https://orcid.org/0000-0001-6440-3763
Freire, Raimundo https://orcid.org/0000-0003-4473-8894
Li, Yuliang
Rottenberg, Sven https://orcid.org/0000-0003-2044-9844
Krastev, Dragomir B. https://orcid.org/0000-0003-4298-7272
Lord, Christopher J. https://orcid.org/0000-0002-3226-0515
Tarsounas, Madalena https://orcid.org/0000-0002-4273-2870
Ramadan, Kristijan https://orcid.org/0000-0001-5522-021X
- License Information
-
More Information
Article History
Received: 10 September 2024
Accepted: 15 April 2026
First Online: 2 June 2026
Competing interests
: C.J.L. receives and/or has received research funding from AstraZeneca, Merck KGaA, Artios, Neophore and FoRx; received consultancy, scientific advisory board membership or honoraria payments from FoRx, Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango Therapeutics, 3rd Rock, Ono Pharma, Artios, Abingworth, Tesselate, Dark Blue Therapeutics, Pontifax, Astex, Neophore, Glaxo Smith Kline, Dawn Bioventures, Blacksmith Medicines, ForEx and Ariceum; and has stock in Tango, Ovibio, Hysplex, Tesselate and Ariceum. C.J.L. is also a named inventor on patents describing the use of DNA repair inhibitors and stands to gain from their development and use as part of the ICR ‘Rewards to Inventors’ scheme, and also reports benefits from this scheme associated with patents for PARP inhibitors paid into C.J.L.’s personal account and research accounts at the Institute of Cancer Research. All other authors declare no competing interests.
